ERBB2 and breast carcinoma: Epirubicin (E) and cyclophosphamide (C) have been widely used in the neoadjuvant setting for HER2-positive breast cancer and a meta-analysis of 8 studies with 5354 available patients confirmed that anthracycline-based adjuvant chemotherapy would add more benefit in disease-free survival (DFS) and overall survival (OS) than non–anthracycline-based adjuvant chemotherapy for HER2-positive breast cancer (7).